Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial
St. Petersburg, FL – November 7, 2022 – Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).